

CURRICULUM VITAE WITH TRACK RECORD

PERSONAL INFORMATION

Killingberg, Kristin Toftaker

Date of birth: 30.11.1968

Sex: Female

Nationality: Norwegian

ORCID <https://orcid.org/0000-0002-1354-9823>

URL

https://scholar.google.com/citations?view_op=list_works&hl=no&user=FbOW2HYAAAAJ

EDUCATION

- | | |
|------|--|
| 2023 | PhD: Twice-daily thoracic radiotherapy in limited stage small-cell lung cancer.
Faculty of Medicine and Health Sciences, Department of Clinical and Molecular Medicine, Norwegian University of Science and technology NTNU, Norway |
| 2017 | Specialist in Oncology, Medical Oncology and Radiotherapy |
| 2008 | Specialist in Family Medicine |
| 1996 | MD:
Faculty of Medicine and Health Sciences, Norwegian University of Science and technology NTNU, Norway |

CURRENT AND PREVIOUS POSITIONS

Current Position

- | | |
|--------|---|
| 2023 - | Post-doc
Faculty of Medicine and Health Sciences, Department of Clinical and Molecular Medicine, Norwegian University of Science and technology NTNU, Norway |
| 2017 - | Senior Consultant in Medical Oncology and Radiotherapy,
The Cancer Clinic, St.Olavs Hospital, Trondheim, with main responsibility for treatment of patient with lung cancer. |

Previous positions held

- | | |
|-----------|---|
| 2016-2017 | Resident, Clinic of Internal Medicine, department of haematology, St. Olavs Hospital, Trondheim |
| 2013-2015 | Resident, The Cancer Clinic, St. Olavs Hospital, Trondheim |
| 2012-2013 | General practitioner (GP), Oppdal kommune, Sør-Trøndelag |
| 2011-2012 | Resident, The Cancer Clinic, St. Olavs Hospital, Trondheim |
| 2008-2011 | General practitioner (GP), Oppdal kommune, Sør-Trøndelag |

2006-2008	Resident, The Cancer Clinic, St. Olavs Hospital, Trondheim, Norway
2002-2006	General practitioner (GP), Rennebu kommune, Sør-Trøndelag
2000-2002	General practitioner (GP), Oppdal kommune, Sør-Trøndelag
1997-1998	Internship in Internal Medicine and Surgery, Hospital of Molde, Internship in General Practice, Aukra kommune, Møre and Romsdal

TEACHING ACTIVITIES

2000-2012	Supervisor for medical students in family medicine
2006 -	Lectures in oncology at several Departments at St. Olavs Hospital, especially the Cancer Clinic, for physicians and specialist-candidates in oncology, (NTNU)
2014-	Instructor at course in communication skills for medical students “breaking bad news”, Norwegian University of science and technology
2010 -	Lectures in cancer therapy for Oncology nurses in Trondheim (NTNU)

MAJOR COLLABORATIONS

Project manager, Bjørn Henning Grønberg (BHG), professor at Department of Clinical and Molecular Medicine, NTNU, and Consultant in Oncology at Department of Oncology, St. St. Olav’s hospital.

He is leader of the Cancer and Palliative Care Research Group (CPRG) at NTNU.

Key members of our laboratory analyses group include:

- Hong Yan Dai (HYD), researcher/molecular biologist, pathology dept., St. Olavs hospital
- Vibeke Grotnes Dale (VGD), consultant in pathology, SOH, specializes in SCLC

Key members of the clinical research group include:

- Tarje Onsøien Halvorsen (TOH), post-doctor, consultant at oncology dept. SOH
- Arne Solberg (AS), researcher, oncologist
- Marie Søfteland Sandvei (MSS), researcher, resident at oncology dept. SOH
- Nina Levin (NL) Msc, Medical physicist, Oncology department, st Olav, PhD candidate NTNU

TRACK RECORD

1. Total number of publications 18

Publications last 10 years 18

- | | | | |
|--------------------------|--|---|------|
| ☐ | Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC | | 2025 |
| | E Taranova, M Aanerud, TO Halvorsen, KT Killingberg, M Slaaen, ...
JTO Clinical and Research Reports 6 (1), 100764 | | |
| ☐ | P1. 13A. 06 Outcomes in LS SCLC Patients with Severe Acute Esophagitis During Chemotherapy and Concurrent Twice-Daily Thoracic Radiotherapy | | 2024 |
| | M Grønberg, TO Halvorsen, BH Grønberg, KT Killingberg, M Aanerud
Journal of Thoracic Oncology 19 (10), S207-S209 | | |
| ☐ | Effect of FDG PET-CT for Staging and Radiotherapy Planning—a Comparison of Cohorts from Two Randomized Trials of Thoracic Radiotherapy in Limited-Stage SCLC | | 2024 |
| | G Graabak, BH Grønberg, KT Killingberg, TO Halvorsen
JTO Clinical and Research Reports, 100688 | | |
| ☐ | Evaluation of Radiation Therapy Treatment Plans in a Randomized Phase 2 Trial Comparing 2 Schedules of Twice-Daily Thoracic Radiation Therapy in Limited Stage Small Cell Lung ... | 2 | 2024 |
| | N Levin, KT Killingberg, TO Halvorsen, S Danielsen, BH Grønberg
International Journal of Radiation Oncology* Biology* Physics | | |
| ☐ | Associations between patient-reported nutritional status, survival, and toxicity among patients with limited stage small-cell lung cancer (LS SCLC) in a randomized trial of ... | 1 | 2023 |
| | E Taranova, BHH Grønberg, TO Halvorsen, KT Killingberg, M Slaaen, ...
Journal of Clinical Oncology 41 (16_suppl), 8519-8519 | | |
| ☐ | Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung ... | 4 | 2023 |
| | BHH Grønberg, KT Killingberg, Ø Fløtten, MM Bjaanæs, T Madebo, ...
Journal of Clinical Oncology 41 (16_suppl), 8512-8512 | | |
| ☐ | Treatment outcomes of older participants in a randomized trial comparing two schedules of twice-daily thoracic radiotherapy in limited-stage SCLC | 5 | 2023 |
| | KT Killingberg, BH Grønberg, M Slaaen, Ø Kirkevold, TO Halvorsen
Journal of Thoracic Oncology 18 (6), 803-812 | | |
| ☐ | Twice-daily thoracic radiotherapy in limited stage small-cell lung cancer | | 2023 |
| | KT Killingberg
NTNU | | |

✓	Associations between measured and patient-reported physical function and survival in advanced NSCLC K Stokke, TO Halvorsen, BH Grønberg, I Saltvedt, M Slaaen, Ø Kirkevold, ... Healthcare 10 (5), 922	2	2022
✓	OC-0440 Comparing target volumes in a randomized trial of high-dose radiotherapy in small cell lung cancer N Levin, S Danielsen, TO Halvorsen, KT Killingberg, KR Redalen, ... Radiotherapy and Oncology 170, S384-S385		2022
✓	Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small ... KT Killingberg, TO Halvorsen, Ø Fløtten, OT Brustugun, SW Langer, ... Lung Cancer 166, 49-57	4	2022
✓	Prognostic value of post first-line chemotherapy Glasgow prognostic score in advanced non-small cell lung cancer K Stokke, MS Sandvei, BH Grønberg, M Slaaen, KT Killingberg, ... Clinical Medicine Insights: Oncology 16, 11795549221086578	5	2022
✓	High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial BH Grønberg, KT Killingberg, Ø Fløtten, OT Brustugun, K Hornslien, ... The Lancet Oncology 22 (3), 321-331	112	2021
✓	Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC TO Halvorsen, K Stokke, KT Killingberg, SX Raj, S Sørhaug, ... Acta Oncologica 59 (9), 1051-1057	6	2020
✓	1783O Patient reported outcomes from a randomized phase II trial comparing standard-dose with high-dose twice daily (BID) thoracic radiotherapy (TRT) in limited stage small ... BH Gronberg, KT Killingberg, K Stokke, TO Halvorsen Annals of Oncology 31, S1032		2020
✓	Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC). BH Gronberg, KT Killingberg, Ø Fløtten, MM Bjaanæs, T Madebo, ... Journal of Clinical Oncology 38 (15_suppl), 9007-9007	10	2020
✓	P1. 01-09 Randomized Trial Comparing Maintenance Pemetrexed with Observation Followed by Pemetrexed at Progression in Advanced NSCLC K Stokke, TO Halvorsen, O Fløtten, S Sørhaug, T Madebo, S Raj, ... Journal of Thoracic Oncology 14 (10), S357-S358		2019
✓	High-Dose Versus Standard Dose Twice-Daily Thoracic Radiotherapy in Limited Stage Small-Cell Lung Cancer: Final Survival Data, Long Term Toxicity and Relapse Patterns in a ... BH Gronberg, KT Killingberg, Ø Fløtten, MM Bjaanæs, OT Brustugun, ...		

3.Conference proceedings

2024 World conference on Lung Cancer

M. Grønberg, T.O. Halvorsen, B.H. Grønberg, K.T. Killingberg, M. Aanerud,
P1.13A.06 Outcomes in LS SCLC Patients with Severe Acute Esophagitis During
Chemotherapy and Concurrent Twice-Daily Thoracic Radiotherapy,
Journal of Thoracic Oncology, Volume 19, Issue 10, Supplement, 2024, Pages S207-S209,
ISSN 1556-0864,
<https://doi.org/10.1016/j.jtho.2024.09.375>.

2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Associations between patient-reported nutritional status, survival, and toxicity among
patients with limited stage small-cell lung cancer (LS SCLC) in a randomized trial of
high-dose, twice-daily (BID) thoracic radiotherapy (TRT).
Evgenia Taranova, Bjorn H. Henning Gronberg, Tarje Onsøien Halvorsen, Kristin
Toftaker Killingberg, Marit Slaaen, Marianne Aanerud
Journal of Clinical Oncology 2023 41:16_suppl, 8519-8519

2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC).

Bjorn H. Henning Gronberg, Kristin Toftaker Killingberg, Øystein Fløtten, Maria Moksnes Bjaanæs, Tesfaye Madebo, Tine Schytte, Seppo Wang Langer, Signe Leonora Risumlund, Nina Helbekkmo, Kirill Neumann, Odd Terje Brustugun, Øyvind Yksnøy, Georgios Tsakonas, Jens Engleson, Sverre Fluge, Thor Naustdal, Liv Ellen Giske, Jan Nyman, Tarje Onsøien Halvorsen
Journal of Clinical Oncology 2023 41:16_suppl, 8512-8512

BiGART,Aarhus, Danmark, 20. juni 2023 ,Acta Oncologica

Dose-response of acute esophagitis for limited stage small cell lung cancer - Data from a randomized phase II trial

Nina Levin ,Signe Danielsen ,Tarje Onsøien Halvorsen, Kristin Toftaker Killingberg,Kathrine Røe Redalen, Bjørn Henning Grønberg

2019 World Conference on Lung Cancer

Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer.

Stokke K, Sandvei MS, Grønberg BH, Slaaen M, Killingberg KT, Halvorsen TO.Clin Med Insights Oncol. 2022 Mar 22; 16:11795549221086578. doi: 10.1177/11795549221086578. eCollection 2022.PMID: 35342321

ESMO Virtual Congress 2020

17830 Patient reported outcomes from a randomized phase II trial comparing standard-dose with high-dose twice daily (BID) thoracic radiotherapy (TRT) in limited stage small ...

BH Gronberg, KT Killingberg, K Stokke, TO Halvorsen
Annals of Oncology 31, S1032

2020 American Society of Clinical Oncology (ASCO) Annual Meeting

Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT) in limited disease small cell lung cancer (LD SCLC)

Bjorn Henning Gronberg, Kristin Toftaker Killingberg, Øystein Fløtten, Maria Moksnes Bjaanæs, Tesfaye Madebo, Seppo Langer, Tine Schytte, Odd Terje Brustugun, Jan Nyman, Kristin Stokke, and Tarje Onsøien Halvorsen
Journal of Clinical Oncology 2020 38:15_suppl, 9007-9007

European Society for Therapeutic Radiology and Oncology (ESTRO) Congress 2022

Target volumes in a randomized trial comparing high-dose versus standard-dose twice daily radiotherapy in limited stage small cell lung cancer.

Nina Levin,Signe Danielsen, Tarje Onsøien Halvorsen, Kristin Toftaker Killingberg, Kathrine Røe Redalen, Bjørn Henning Grønberg .

2. Prizes/ Awards/ Academy memberships

Publikasjonsprisen 2021 Institutt for klinisk og molekylær medisin ,NTNU

Bjørn Henning Grønberg, Kristin T Killingberg og Tarje Halvorsen

For the publication In Lancet Oncology : High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small cell lung cancer: an open-label, randomised,phase 2 trial

Årets publikasjon 2021 st Olavs hospital

“High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomized phase 2 trial” - The Lancet Oncology 2021; 22(3): 321-331

Kreftklinikken v. Bjørn Henning Grønberg, Kristin T Killingberg og Tarje Halvorsen